Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine. Dr Park also provides his assessment of Korea’s challenge in commercialising its academic research.
NOV not only supports research financially but also co-develops the chosen oncology drug candidate in collaboration with the originator. This differentiates us from other government R&D support initiatives which are fund supporting programs
